Co-Authors
This is a "connection" page, showing publications co-authored by Leike Zhang and Gengfu Xiao.
Connection Strength
4.460
-
Author Correction: Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov. 2021 May 03; 7(1):29.
Score: 0.943
-
Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. Cell Discov. 2020 Dec 22; 6(1):96.
Score: 0.920
-
Comprehensive interactome analysis of the spike protein of swine acute diarrhea syndrome coronavirus. Biosaf Health. 2021 Jun; 3(3):156-163.
Score: 0.236
-
High-Throughput Screening of an FDA-Approved Drug Library Identifies Inhibitors against Arenaviruses and SARS-CoV-2. ACS Infect Dis. 2021 06 11; 7(6):1409-1422.
Score: 0.228
-
Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Virol Sin. 2020 Dec; 35(6):776-784.
Score: 0.226
-
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 03; 30(3):269-271.
Score: 0.216
-
A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection. Antiviral Res. 2019 05; 165:11-22.
Score: 0.203
-
Novel neutralizing monoclonal antibodies against Junin virus. Antiviral Res. 2018 08; 156:21-28.
Score: 0.193
-
Quantitative Proteomic Analysis of Mosquito C6/36 Cells Reveals Host Proteins Involved in Zika Virus Infection. J Virol. 2017 06 15; 91(12).
Score: 0.179
-
Global quantitative proteomic analysis profiles host protein expression in response to Sendai virus infection. Proteomics. 2017 03; 17(5).
Score: 0.177
-
Decreased inhibition of exosomal miRNAs on SARS-CoV-2 replication underlies poor outcomes in elderly people and diabetic patients. Signal Transduct Target Ther. 2021 08 11; 6(1):300.
Score: 0.060
-
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun. 2021 06 15; 12(1):3623.
Score: 0.059
-
SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 2021 08; 31(8):847-860.
Score: 0.059
-
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell. 2021 11; 12(11):877-888.
Score: 0.059
-
Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat Struct Mol Biol. 2021 03; 28(3):319-325.
Score: 0.058
-
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2021 Jan; 12(1):76-80.
Score: 0.058
-
Correction to: Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020 Nov 09.
Score: 0.057
-
Decreased HD-MIR2911 absorption in human subjects with the SIDT1 polymorphism fails to inhibit SARS-CoV-2 replication. Cell Discov. 2020; 6:63.
Score: 0.056
-
Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Discov. 2020; 6(1):54.
Score: 0.056
-
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. Protein Cell. 2020 10; 11(10):723-739.
Score: 0.056
-
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin. 2020 Sep; 41(9):1167-1177.
Score: 0.056
-
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020 06; 27(6):529-532.
Score: 0.055
-
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020 06 19; 368(6497):1331-1335.
Score: 0.055
-
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 06; 582(7811):289-293.
Score: 0.055
-
Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. J Virol. 2018 08 15; 92(16).
Score: 0.049
-
Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection. J Virol. 2017 11 01; 91(21).
Score: 0.046
-
Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res. 2017 05; 141:140-149.
Score: 0.044